NSG6005 ADVANCED PHARMACOLOGY FINAL EXAM TEST BANK. ALL CHAPTERS COVERED. ( QUESTIONS AND ANSWERS GRADED A+ 2022

Chapter 49. Men as Patients 1. The factor that has the greatest effect on males developing male sexual characteristics is: A. Cultural beliefs B. Effective male role models C. Adequate intake of testosterone in the diet D. Estrogen production 2. When assessing a male for hypogonadism prior to prescribing testosterone replacement, serum testosterone levels are drawn: A. Without regard to time of day B. First thing in the morning C. Late afternoon D. In the evening 3. Some research supports that testosterone replacement therapy may be indicated in which of the following diagnoses in men? A. Age-related decrease in cognitive functioning B. Metabolic syndrome C. Decreased muscle mass in aging men D. All of the above 4. The goal of testosterone replacement therapy is: A. Absence of all hypogonadism symptoms B. Testosterone levels in the mid-normal range 1 week after an injection C. Testosterone levels in the mid-normal range just prior to the next injection D. Avoidance of high serum testosterone levels during therapy 5. While on testosterone replacement, hemoglobin & hematocrit levels should be monitored. Levels suggestive of excessive erythrocytosis or abuse are: A. Hemoglobin 14 g/dl or hematocrit 39% B. Hemoglobin 11.5 g/dl or hematocrit 31% C. Hemoglobin 13 g/dl or hematocrit 38% D. Hemoglobin 17.5 g/dl or hematocrit 54% 6. Monitoring of an older male patient on testosterone replacement includes: A. Oxygen saturation levels at every visit B. Serum cholesterol & lipid profile every 3 to 6 months C. Digital rectal prostate screening exam at 3 & 6 months after starting therapy D. Bone mineral density at 3 months & 6 months after starting therapy 7. When prescribing phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil (Viagra) patients should be screened for use of: A. Statins B. Nitrates C. Insulin D. Opioids 8. Men who are prescribed phosphodiesterase type 5 (PDE-5) inhibitors for erectile dysfunction should be educated regarding the adverse effects of the drug which include: A. Hearing loss B. Hypotension C. Delayed ejaculation D. Dizziness 9. Male patients who should not be prescribed phosphodiesterase type 5 (PDE5) inhibitors include: A. Diabetics B. Those who have had an acute myocardial infarction in the past 6 months C. Patients who are deaf D. Patients under age 60 years of age 10. Monitoring of male patients who are using phosphodiesterase type 5 (PDE-5) inhibitors includes: A. Serum fasting glucose levels B. Cholesterol & lipid levels C. Blood pressure D. Complete blood count Chapter 50. Children as Patients 1. The Pediatric Research Equity Acts requires: 2. All children be provided equal access to drug research trials 3. Children to be included in the planning phase of new drug development 4. That pediatric drug trials guarantee children of multiple ethnic groups are included 5. All applications for new active ingredients, new indications, new dosage forms, or new routes of administration require pediatric studies 2. The Best Pharmaceuticals for Children Act: 1. Includes a pediatric exclusivity rule which extends the patent on drugs studied in children 2. Establishes a committee that writes guidelines for pediatric prescribing 3. Provides funding for new drug development aimed at children 4. Encourages manufacturers specifically to develop pediatric formulations 3. The developmental variation in Phase I enzymes has what impact on pediatric prescribing? 1. None, Phase I enzymes are stable throughout childhood. 2. Children should always be prescribed lower than adult doses per weight due to low enzyme activity until puberty. 3. Children should always be prescribed higher than adult doses per weight due to high enzyme activity. 4. Prescribing dosages will vary based on the developmental activity of each enzyme, at times requiring lower than adult doses & other times higher than adult doses based on the age of the child. 4. Developmental variation in renal function has what impact on prescribing for infants & children? 1. Lower doses of renally excreted drugs may be prescribed to infants younger than age 6 months. 2. Higher doses of water soluble drugs may need to be prescribed because of increased renal excretion. 3. Renal excretion rates have no impact on prescribing. S - The Marketplace to Buy and Sell your Study Material Downloaded by: butterflyrn1985 | Distribution of this document is illegal S - The Marketplace to Buy and Sell your Study Material 4. Parents need to be instructed on whether drugs are renally excreted or not. 5. Topical corticosteroids are prescribed cautiously in young children because: 1. They may cause an intense hypersensitivity reaction 2. Of hypothalamic-pituitary-adrenal axis suppression 3. Corticosteroids are less effective in young children 4. Young children may accumulate corticosteroids, leading to toxic levels 6. Liza is breastfeeding her 2-month-old son & has an infection that requires an antibiotic. What drug factors influence the effect of the drug on the infant? 1. Maternal drug levels 2. Half-life 3. Lipid-solubility 4. All of the above